Gilead’s short-term win could come at massive cost to the future of pharmaceutical innovation and to the health of the American public. The U.S. government filed the lawsuit in 2019, alleging ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue ...

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...

([content-module:CompanyOverview, NASDAQ:GILD) Gilead Sciences Inc. (NASDAQ:GILD) stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...

Gilead to report Q4 earnings on Feb. 11, with analysts expecting $1.70 EPS and $7.14B in revenue. Gilead's deal with LEO Pharma includes a $250M upfront payment and up to $1.7B in milestones ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. The quarter saw substantial revenue growth, encouraging confidence in Gilead ...

Shares of Gilead (NASDAQ:GILD) rose 6% post-market after the company released a Q4 earnings report that beat the Street and hiked its quarterly dividend. For Q4, Gilead (NASDAQ:GILD) posted non ...